JMP Securities reissued their buy rating on shares of Bicycle Therapeutics (NASDAQ:BCYC – Get Rating) in a research note published on Thursday morning. They currently have a $70.00 price objective on the stock.
BCYC has been the subject of a number of other research reports. Piper Sandler reduced their price target on Bicycle Therapeutics from $76.00 to $37.00 and set an overweight rating for the company in a research report on Monday, May 23rd. SVB Leerink boosted their price target on Bicycle Therapeutics from $48.00 to $50.00 and gave the stock an outperform rating in a research report on Monday, August 22nd. HC Wainwright reduced their price target on Bicycle Therapeutics from $65.00 to $57.00 and set a buy rating for the company in a research report on Friday, August 5th. Barclays began coverage on Bicycle Therapeutics in a research note on Thursday, July 28th. They issued an overweight rating and a $30.00 price objective on the stock. Finally, Canaccord Genuity Group reissued a buy rating and issued a $60.00 price objective on shares of Bicycle Therapeutics in a research note on Wednesday, July 6th. Two analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of Moderate Buy and an average target price of $57.08.
Bicycle Therapeutics Trading Down 0.9 %
NASDAQ:BCYC opened at $25.10 on Thursday. Bicycle Therapeutics has a 12-month low of $12.08 and a 12-month high of $62.08. The firm has a market capitalization of $744.87 million, a P/E ratio of -8.23 and a beta of 0.71. The company has a debt-to-equity ratio of 0.10, a current ratio of 9.88 and a quick ratio of 9.88. The business has a 50 day simple moving average of $23.65 and a 200 day simple moving average of $26.47.
Institutional Inflows and Outflows
Several large investors have recently bought and sold shares of the business. DekaBank Deutsche Girozentrale raised its position in Bicycle Therapeutics by 10.0% during the first quarter. DekaBank Deutsche Girozentrale now owns 13,200 shares of the company’s stock valued at $562,000 after buying an additional 1,200 shares during the period. Prospera Financial Services Inc purchased a new position in Bicycle Therapeutics in the first quarter valued at about $88,000. State Street Corp grew its stake in Bicycle Therapeutics by 27.9% in the first quarter. State Street Corp now owns 10,687 shares of the company’s stock valued at $469,000 after purchasing an additional 2,333 shares in the last quarter. Quantbot Technologies LP purchased a new position in Bicycle Therapeutics in the second quarter valued at about $60,000. Finally, Claro Advisors LLC purchased a new position in Bicycle Therapeutics in the fourth quarter valued at about $221,000. 76.45% of the stock is owned by institutional investors and hedge funds.
About Bicycle Therapeutics
Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. Its lead product candidate is BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease.
- Get a free copy of the StockNews.com research report on Bicycle Therapeutics (BCYC)
- Oil and Gas Stocks: A Safe Way to Invest in Renewable Energy
- When Will the Hangover Finally Be Over for Seagate Technology?
- Are These Green Energy Companies Right For Your Portfolio?
- Does Enphase Energy Have the Juice to Keep Powering Higher?
- The One Hydrogen Fuel Cell Stock To Rule Them All
Receive News & Ratings for Bicycle Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bicycle Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.